Nexalin Technology has announced positive results from a clinical study evaluating its Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs (VA) San Diego Healthcare System, as well as the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego. This research sheds light on the potential of this technology to address a significant concern for veterans and the general public, as mTBI leads to various physical, cognitive, emotional, and behavioral deficits. Effective treatments for post-concussive symptoms (PCS) have been limited, and the underlying pathophysiology is not fully understood. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), further complicating diagnosis and treatment.
The clinical trial was conducted as a randomized, double-blind, placebo-controlled study over an eight-week period, involving two groups: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve sessions of either active or sham tACS over four consecutive weeks, followed by a four-week follow-up period to assess outcomes. The positive results from this study are significant, especially considering the substantial market potential for treatments addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032. Nexalin's innovative approach offers promise in addressing the needs of individuals suffering from mTBI, potentially improving their quality of life and providing hope for effective treatment options in the future. The collaboration with major institutions like the VA San Diego Healthcare System and UC San Diego underscores the credibility and importance of this research in the medical community.
The implications of this announcement extend beyond the immediate patient population. With traumatic brain injuries being a growing public health concern, particularly among military veterans who experience higher rates of mTBI due to combat and training exposures, the development of effective non-pharmacological interventions represents a critical advancement. Current treatment options often rely on medications that may have side effects or limited efficacy, leaving many patients without adequate relief from chronic pain and other debilitating symptoms. The Gen-2 tACS device, as studied in this trial, could offer a safer alternative by using targeted electrical stimulation to modulate brain activity associated with pain perception.
From a broader perspective, the success of this clinical trial could accelerate regulatory approvals and insurance coverage for tACS technology, making it more accessible to patients beyond veteran populations. The projected growth of the traumatic brain injuries assessment market, as highlighted by sources like Global Market Insights, indicates increasing investment and interest in this field, which could drive further innovation and competition. For Nexalin Technology, these results position the company as a leader in neuromodulation therapies, potentially attracting partnerships or funding to expand research into other neurological conditions. Ultimately, this study matters because it addresses a pressing healthcare challenge with a novel solution that could transform patient care and outcomes in a market poised for significant expansion.
